Communiqués Alps Group Inc

Actions

Cours en clôture Nasdaq 19/08/2026			Varia. 5j.	Varia. 1 janv.
0,2700 ^USD	-8,66%		-15,62%	-68,94%

23/06	Alps Group Inc lance un programme d’organoïdes dérivés de patients pour faire progresser la prise en charge personnalisée du cancer en Asie du Sud-Est	CI
19/05	Alps Group reçoit un avis de non-conformité du Nasdaq	MT

07/08	Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update	AQ
23/06	Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia	AQ
09/06	Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022	AQ
19/05	Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency	AQ
17/04	Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight	GL
23/02	Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol	GL
23/02	Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol	AQ
30/01	Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy	GL
08/01	Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer	GL
08/01	Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer	AQ